---
schema_version: "secwatch.filing_event.v1"
accession: "0001601485-25-000022"
form_type: "8-K"
ticker: "ELTX"
cik: "0001601485"
company_name: "Elicio Therapeutics, Inc."
filed_at: "2025-03-24T23:59:59+00:00"
generated_at: "2026-05-24T06:33:43.919542+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Elicio Therapeutics appoints Preetam Shah as Chief Strategy and Financial Officer

## Summary
- Preetam Shah appointed Chief Strategy and Financial Officer effective March 24, 2025; will become Principal Financial Officer and Principal Accounting Officer on April 1, 2025.
- Annual base salary $480,000; target bonus of 40% of base; initial option grant equal to 1.2% of outstanding shares as of April 15, 2025, vesting over 4 years.
- Shah previously served as CFO/CBO at Cidara Therapeutics (Sept 2021–Feb 2025) and CFO & Treasurer at Brainstorm Cell Therapeutics (Sept 2019–Aug 2021).
- The company highlights upcoming Phase 2 AMPLIFY-7P disease-free survival interim analysis for cancer immunotherapy ELI-002.

## SEC filing metadata
- accession: 0001601485-25-000022
- form_type: 8-K
- ticker: ELTX
- cik: 0001601485
- company_name: Elicio Therapeutics, Inc.
- filed_at: 2025-03-24T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1601485/000160148525000022/0001601485-25-000022-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1601485/000160148525000022/angn-20250321.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001601485-25-000022
- JSON: https://secwatch.observer/filing/0001601485-25-000022.json
- Plain text: https://secwatch.observer/filing/0001601485-25-000022.txt

## Key facts
- Executive change
  Preetam Shah was appointed as Chief Strategy and Financial Officer at Elicio Therapeutics, Inc..
  - Action: appointed
  - Role: Chief Strategy and Financial Officer
  source text: On March 21, 2025, Elicio Therapeutics, Inc. (the “Company”) appointed Preetam Shah, Ph.D., M.B.A., as the Company’s Chief Strategy and Financial Officer effective as of March 24, 2025 (the “Effective Date”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1601485/000160148525000022/0001601485-25-000022-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.